• Ying Fan, Shusen Yang, Yang Cao, and Yonglin Huang.
• Department of Cardiology, The First Affiliated Hospital of Harbin Medical University, Heilongjiang, China.
• Cardiovasc Ther. 2013 Aug 1;31(4):187-92.

BackgroundMyocardial reperfusion therapy remains the most effective strategy to limit infarct size and improve clinical outcome. However, reperfusion injury is still inevitable, and a number of strategies have been developed to ameliorate its lethal outcome. The beneficial roles of ischemic postconditioning (Ipost) have regained more interest in targeting myocardial reperfusion phase to improve cardioprotection.AimsThis study was to determine whether acute or chronic treatment with atorvastatin affects cardioprotection when it was combined with Ipost.ResultsAcute or chronic atorvastatin treatment significantly reduced infarct size and recovered contractile dysfunction during reperfusion. When Ipost was combined with atorvastatin treatment, chronic, but not acute, atorvastatin therapy attenuated the cardioprotective effects of Ipost. Chronic, but not acute, atorvastatin treatment also abolished Ipost-induced phosphorylation level of Akt and endothelial nitric oxide synthase (eNOS).ConclusionsChronic atorvastatin treatment could interfere with cardioprotective effects of Ipost on limiting infarct size and contractile dysfunction, possibly via inhibition of Akt and eNOS activity. This study suggests that Ipost should be used carefully when atorvastatin is taken by patients with AMI.© 2012 John Wiley & Sons Ltd.

41 keywords...

hide…